Erythromycin Formulations-A Journey to Advanced Drug Delivery

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Oct 27

PMID 36297615

Authors

Vera-Maria Platon

Brindusa Dragoi

Luminita Marin

Affiliations

Soon will be listed here.

Abstract

Erythromycin (ERY) is a macrolide compound with a broad antimicrobial spectrum which is currently being used to treat a large number of bacterial infections affecting the skin, respiratory tract, intestines, bones and other systems, proving great value from a clinical point of view. It became popular immediately after its discovery in 1952, due to its therapeutic effect against pathogens resistant to other drugs. Despite this major advantage, ERY exhibits several drawbacks, raising serious clinical challenges. Among them, the very low solubility in water and instability under acidic conditions cause a limited efficacy and bioavailability. Apart from this, higher doses promote drug resistance and undesirable effects. In order to overcome these disadvantages, during the past decades, a large variety of ERY formulations, including nanoparticles, have emerged. Despite the interest in ERY-(nano)formulations, a review on them is lacking. Therefore, this work was aimed at reviewing all efforts made to encapsulate ERY in formulations of various chemical compositions, sizes and morphologies. In addition, their preparation/synthesis, physico-chemical properties and performances were carefully analysed. Limitations of these studies, particularly the quantification of ERY, are discussed as well.

Citing Articles

Heteroleptic Coumarin-Based Silver(I) Complexes: Possible New Antimicrobial Agents.

Mooney E, Twamley B, Cooke G, Caraher E, Tacke M, Kelleher F Molecules. 2025; 29(24.

PMID: 39770006 PMC: 11678713. DOI: 10.3390/molecules29245917.

Cyclodextrins: Advances in Chemistry, Toxicology, and Multifaceted Applications.

Musuc A Molecules. 2024; 29(22).

PMID: 39598708 PMC: 11596893. DOI: 10.3390/molecules29225319.

Heterologous Expression of Type II PKS Gene Cluster Leads to Diversified Angucyclines in J1074.

Zhang X, Zhang F, Li C, Li J, Xu X, Zhu T Mar Drugs. 2024; 22(11).

PMID: 39590760 PMC: 11595736. DOI: 10.3390/md22110480.

Combinations of (Gaertn.) Roxb. and Retz. Extracts with Selected Antibiotics Against Antibiotic-Resistant Bacteria: Bioactivity and Phytochemistry.

Tiwana G, Cock I, Cheesman M Antibiotics (Basel). 2024; 13(10).

PMID: 39452260 PMC: 11504310. DOI: 10.3390/antibiotics13100994.

Erythromycin-metal complexes: One-step synthesis, molecular docking analysis and antibacterial proficiency against pathogenic strains.

Egu S, Abah L, Hussaini J, Onoja A, Ali I, Habib A Heliyon. 2024; 10(16):e35536.

PMID: 39220992 PMC: 11363837. DOI: 10.1016/j.heliyon.2024.e35536.

References

Wu V, Tang S, Uskokovic V . Calcium Phosphate Nanoparticles as Intrinsic Inorganic Antimicrobials: The Antibacterial Effect. ACS Appl Mater Interfaces. 2018; 10(40):34013-34028. DOI: 10.1021/acsami.8b12784. View

Wang X, Chen D, Cao L, Li Y, Boyd B, Caruso R . Mesoporous titanium zirconium oxide nanospheres with potential for drug delivery applications. ACS Appl Mater Interfaces. 2013; 5(21):10926-32. DOI: 10.1021/am4031104. View

Zgoulli S, Grek V, Barre G, Goffinet G, Thonart P, Zinner S . Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. J Microencapsul. 1999; 16(5):565-71. DOI: 10.1080/026520499288762. View

Juric S, Stracenski K, Krol-Kilinska Z, Zutic I, Fabek Uher S, dermic E . The enhancement of plant secondary metabolites content in Lactuca sativa L. by encapsulated bioactive agents. Sci Rep. 2020; 10(1):3737. PMC: 7048752. DOI: 10.1038/s41598-020-60690-3. View

Ha P, Van Schepdael A, Roets E, Hoogmartens J . Investigating the potential of erythromycin and derivatives as chiral selector in capillary electrophoresis. J Pharm Biomed Anal. 2004; 34(5):861-70. DOI: 10.1016/j.jpba.2003.11.004. View

HEILMAN F, HERRELL W, WELLMAN W, GERACI J . Some laboratory and clinical observations on a new antibiotic, erythromycin (ilotycin). Proc Staff Meet Mayo Clin. 1952; 27(15):285-304. View

Doostan M, Maleki H, Doostan M, Khoshnevisan K, Faridi-Majidi R, Arkan E . Effective antibacterial electrospun cellulose acetate nanofibrous patches containing chitosan/erythromycin nanoparticles. Int J Biol Macromol. 2020; 168:464-473. DOI: 10.1016/j.ijbiomac.2020.11.174. View

Habbema L, Koopmans B, Menke H, Doornweerd S, De Boulle K . A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. Br J Dermatol. 1989; 121(4):497-502. DOI: 10.1111/j.1365-2133.1989.tb15518.x. View

Filipczak N, Pan J, Yalamarty S, Torchilin V . Recent advancements in liposome technology. Adv Drug Deliv Rev. 2020; 156:4-22. DOI: 10.1016/j.addr.2020.06.022. View

10.

Weber Jr F, Richards R, McCallum R . Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol. 1993; 88(4):485-90. View

11.

Natsheh H, Touitou E . Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties. Molecules. 2020; 25(13). PMC: 7412180. DOI: 10.3390/molecules25132959. View

12.

Dyab A, Mohamed M, Meligi N, Mohamed S . Encapsulation of erythromycin and bacitracin antibiotics into natural sporopollenin microcapsules: antibacterial, cytotoxicity, and release studies for enhanced bioavailability. RSC Adv. 2022; 8(58):33432-33444. PMC: 9086482. DOI: 10.1039/c8ra05499a. View

13.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

14.

Sayyafan M, Ramzi M, Salmanpour R . Clinical assessment of topical erythromycin gel with and without zinc acetate for treating mild-to-moderate acne vulgaris. J Dermatolog Treat. 2019; 31(7):730-733. DOI: 10.1080/09546634.2019.1606394. View

15.

Shah S, Misra A . Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech. 2005; 5(4):e65. PMC: 2750490. DOI: 10.1208/pt050465. View

16.

Jeong S, Lee J, Im B, Park H, Na K . Combined photodynamic and antibiotic therapy for skin disorder via lipase-sensitive liposomes with enhanced antimicrobial performance. Biomaterials. 2017; 141:243-250. DOI: 10.1016/j.biomaterials.2017.07.009. View

17.

de Meyer F, Smit B . Effect of cholesterol on the structure of a phospholipid bilayer. Proc Natl Acad Sci U S A. 2009; 106(10):3654-8. PMC: 2656135. DOI: 10.1073/pnas.0809959106. View

18.

Joachim C . To be nano or not to be nano?. Nat Mater. 2005; 4(2):107-9. DOI: 10.1038/nmat1319. View

19.

Yamamura H, Hagiwara T, Hayashi Y, Osawa K, Kato H, Katsu T . Antibacterial Activity of Membrane-Permeabilizing Bactericidal Cyclodextrin Derivatives. ACS Omega. 2021; 6(47):31831-31842. PMC: 8638021. DOI: 10.1021/acsomega.1c04541. View

20.

Montenez J, Van Bambeke F, Piret J, Brasseur R, Tulkens P, Mingeot-Leclercq M . Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol. 1999; 156(2):129-40. DOI: 10.1006/taap.1999.8632. View